AMGN vs PFE: fair value comparison
Amgen Inc. and Pfizer Inc. · Updated 2026-08-31
Both currently screen as overvalued on TickrTrends' Forward Fair Value model. Within Healthcare, PFE currently sits closer to the top of our discount ranking. AMGN carries the stronger quality grade. PFE carries the stronger momentum grade.
| AMGN | PFE | |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Last price | $432.42 | $27.96 |
| 12-month range | $286.92–$385.70 | $24.23–$28.55 |
| Sector rank | #104 of 113 Healthcare | #100 of 113 Healthcare |
| Quality grade | B | F |
| Momentum grade | C | A |
| Leverage | High | Moderate |
| Margin trend | Stable | Expanding |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The top quarter |
Full single-stock breakdowns: AMGN fair value analysis · PFE fair value analysis